Synthesis and Biological Evaluation of New 1,2,3-Triazole-piperzine-quinazolines as Potent Anticancer Agents

Objective: The current study aimed to develop novel 1,2,3-triazole-piperzine-quinazolines and test their anticancer potential against MCF-7, HeLa, A-549, and HEK-293. Methods: Initially, we combined 4-chloro-2-methylquinazoline with 1-(prop-2-yn-1-yl)piperazine to produce the key intermediate alkyne. Following this, various aryl azides reacted with alkyne to produce the final 1,2,3-triazoles. We evaluated the anticancer activity of the newly synthesized derivatives using the MTT microcultured tetrazolium assay, which measures cell viability. Results and discussion: ESI-MS, ¹H, and ¹³C NMR spectroscopy show the verification of all the prepared derivatives. Compounds (IVe) and (IVk) are demonstrated more potent activity against MCF-7 with IC₅₀ values of 3.03 ± 0.34 and 3.18 ± 0.42 μM. And also compounds (IVd) and (IVl) have shown good activity against MCF-7, with IC₅₀ values of 4.23 ± 0.54 and 6.32 ± 0.61 μM. These results are compared to the standard doxorubicin. Conclusions: A novel series of 1,2,3-triazole-piperzine-quinazoline conjugates were synthesized and tested for in vitro anticancer activity. Some of the compounds had strong activity against MCF-7 and good activity against the A-549 cell lines. More powerful compounds did not harm the normal cell line, HEK-293. Finally, by making a modest alteration to powerful compounds, it has the potential to be a future therapeutic candidate for cancer treatment.